Evidence map›Paper›PMID 40438201›Full record

ArticleRegenerative biomaterials2025

Recombinant human fibronectin segment (rhFN

Jianhang Cong, Yating Cheng, Tongtong Liu, Xiang Cai, Jiahui Xu, Rui Guo, Rongrong He, Qi Xiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jianhang CongState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou 510632, China.
Yating ChengState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou 510632, China.ORCID https://orcid.org/0000-0001-5357-2561
Tongtong LiuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou 510632, China.
Xiang CaiState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou 510632, China.
Jiahui XuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou 510632, China.
Rui GuoKey Laboratory of Biomaterials of Guangdong Higher Education Institutes, Guangdong Provincial Engineering and Technological Research Center for Drug Carrier Development, Department of Biomedical Engineering, Jinan University, Guangzhou 510632, China.
Rongrong HeState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou 510632, China.
Qi XiangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou 510632, China.ORCID https://orcid.org/0000-0001-9790-5823

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The accumulation of advanced glycation end products (AGEs) plays a crucial role in chronic inflammation and delayed wound healing in individuals with diabetes. In this context, fibronectin has been identified as a crucial protein that promotes the differentiation of human periodontal ligament stem cells (hPDLSCs) into myofibroblasts, which play a vital role in the repair of diabetic skin ulcers. This process is intimately associated with the integrin β1 receptor and the NF-κB signaling pathway, both crucial for cellular responses to fibronectin. To validate our hypothesis, we expressed rhFN

Indexed as

advanced glycation end productshuman periodontal ligament stem cells differentiation myofibroblastsintegrin β1nuclear factor kappa-B signaling pathwayrecombinant human fibronectin peptide

Identifiers

PMID40438201
PMCPMC12119132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.